Eloralintide vs Retatrutide: Data Compared

Eloralintide vs Retatrutide: Data Compared. Eloralintide vs retatrutide compared: selective amylin vs triple agonist mechanism, Phase 2 48-week data, tolerability, and research-use status. Key Takeaways Different mechanisms, not different strengths: Eloralintide is a selective amylin receptor agonist. Retatrutide is a triple agonist at GIP, GLP-1, and glucagon receptors. Eloralintide Phase 2: 263 adults, 48 weeks, mean weight reductions of 9.5%-20.1% versus 0.4% for placebo, with about 20.1% at the 9 mg dose. Retatrutide Phase 2: 338 participants, 48 weeks, mean weight reduction up to 24.2% (roughly 26.2 kg) at the highest dose evaluated. Tolerability is the real differentiator: Eloralintide's most common adverse events were mild-to-moderate GI symptoms, with incidence similar to placebo in the lower dose arms. No head-to-head trial exists: Every number below comes from two separate Phase 2 programs, so the comparison is directional only. Both are investigational: Neither eloralintide nor retatrutide is FDA-approved. Material sold under these names is for laboratory research use only. Eloralintide vs retatrutide has become one of the most-searched comparisons in the obesity peptide literature, and most write-ups get it wrong by treating it as a horsepower contest. It is not. These two Eli Lilly candidates act on completely different biology: retatrutide stacks three incretin and glucagon signals into one molecule, while eloralintide narrows the target down to a single satiety pathway — the amylin receptor. This article compares mechanism, Phase 2 trial design, reported efficacy, tolerability signals, and research-use status. It also explains, in plain terms, why the headline percentages from the two programs cannot be stacked against each other as if they came from the same study. Quick Comparison: Eloralintide vs Retatrutide Attribute Eloralintide Retatrutide Developer Eli Lilly Eli Lilly Class Selective amylin receptor agonist (LY-3841136 class) Triple agonist (LY3437943) Receptors targeted Amylin receptor only GIP + GLP-1 + glucagon Administration in trials Once weekly Once weekly, subcutaneous Phase 2 population 263 adults with obesity or overweight plus at least one obesity-related comorbidity, without type 2 diabetes 338 participants with obesity or overweight with weight-related conditions, excluding type 2 diabetes Phase 2 duration 48 weeks 48 weeks Reported mean weight reduction 9.5%-20.1% across arms vs 0.4% placebo (~20.1% at 9 mg) Up to 24.2% (~26.2 kg / ~58 lb) at the highest dose Tolerability signal Mild-to-moderate GI events; incidence similar to placebo in lower dose arms GI events are the dominant class effect, and burden rises with dose Regulatory status Investigational, not FDA-approved Investigational, not FDA-approved What Is Eloralintide? Eloralintide is Eli Lilly's investigational, once-weekly selective amylin receptor agonist . Amylin is a pancreatic hormone co-secreted with insulin that signals satiety and slows gastric emptying. Selectivity is the design point: rather than also hitting calcitonin-family receptors or bolting amylin activity onto a GLP-1 backbone, eloralintide is engineered to engage the amylin receptor specifically. That matters because the field's dominant strategy for the last decade has been additive — more receptors, more signal, more weight loss. Eloralintide tests the opposite hypothesis: that one well-chosen satiety pathway, cleanly targeted, can deliver competitive efficacy with a gentler adverse-event profile. Readers tracking the adjacent amylin analog work can compare this with our explainer on what cagrilintide peptide is used for , since cagrilintide is the amylin component inside Novo Nordisk's CagriSema combination. What Is Retatrutide? Retatrutide (LY3437943) is Eli Lilly's investigational once-weekly triple hormone receptor agonist . A single molecule activates GIP, GLP-1, and glucagon receptors. GLP-1 and GIP cover incretin biology — appetite suppression, glucose-dependent insulin secretion, slowed gastric emptying — while glucagon receptor activity is included for its potential effects on energy expenditure, fat oxidation, and liver metabolism. Retatrutide is the current high-water mark for reported Phase 2 weight reduction in this class, which is exactly why it is the compound everything else gets measured against. For the broader field context, our CagriSema vs retatrutide comparison covers the combination-versus-single-molecule debate, and our mazdutide vs tirzepatide vs retatrutide breakdown places it against the dual-agonist candidates. Mechanism: One Pathway vs Three The cleanest way to frame eloralintide vs retatrutide is scope of action. Retatrutide is a breadth strategy. Eloralintide is a precision strategy. Breadth buys efficacy ceiling. Hitting GIP, GLP-1, and glucagon receptors simultaneously lets a single molecule act on appetite, insulin secretion, and energy expenditure at once, and the Phase 2 numbers reflect that. The cost is pharmacologic surface area: more pathways engaged means more systems that can produce unwanted effects, and glucagon receptor agonism in particular has to be balanced carefully against the glucose-lowering arms of the molecule. Precision buys tolerability headroom. Amylin signaling is a satiety mechanism rather than an incretin mechanism, so a selective amylin agonist is not simply a weaker GLP-1 drug — it is a different lever on food intake. That distinction is the whole reason the eloralintide readout is interesting: the reported adverse-event profile in the lower dose arms was similar to placebo, which is not a sentence that typically appears next to double-digit weight reduction in this class. Phase 2 Data Side by Side Eloralintide. The randomized, double-blind, placebo-controlled, multicentre Phase 2 study enrolled 263 adults with obesity or overweight plus at least one obesity-related comorbidity, without type 2 diabetes, and ran 48 weeks. All dose arms met the primary endpoint. Mean weight reductions ranged from 9.5% to 20.1% versus 0.4% for placebo on the efficacy estimand, with roughly 20.1% observed at the 9 mg dose. The study also reported improvements across cardiometabolic risk factors including waist circumference, blood pressure, lipids, glycemic control, and inflammation markers. Results were presented at ObesityWeek 2025 and published in The Lancet , and Lilly indicated plans to begin Phase 3 enrollment by the end of 2025 ( Eli Lilly investor release ). Retatrutide. The Phase 2 obesity trial published in the New England Journal of Medicine enrolled 338 participants with obesity or overweight with weight-related conditions, excluding type 2 diabetes, and evaluated subcutaneous weekly doses up to 12 mg. At 48 weeks the highest dose produced mean weight reduction up to 24.2%, roughly 26.2 kg or about 58 lb. An earlier 24-week readout from the same program showed up to 17.5%, which is a useful reminder that duration alone moves these numbers substantially ( NEJM ). Why the Numbers Cannot Be Ranked Directly The short answer: there is no head-to-head trial. Eloralintide and retatrutide have never been randomized against each other, so 20.1% and 24.2% are two separate measurements taken with two separate rulers. What makes the comparison unusually fair is that both Phase 2 programs ran 48 weeks in adults with obesity or overweight without type 2 diabetes. What keeps it directional rather than definitive: different sample sizes (263 vs 338), different dose ranges and escalation schedules, different baseline characteristics, and different statistical estimands and missing-data conventions. A 4-point gap between separate trials is well inside the range that trial design alone can produce. Tolerability: Where Eloralintide Gets Interesting In the eloralintide Phase 2 study, the most common adverse events were mild-to-moderate gastrointestinal symptoms, and incidence was similar to placebo in the lower dose arms. That is the single most notable line in the readout, because gastrointestinal burden is the standard limiting factor across this drug class. Retatrutide's Phase 2 experience follows the class pattern: GI events are the dominant adverse-event category and the burden scales with dose. Our guide to retatrutide side effects covers what the published trial literature reports in more detail. Read together, the two profiles suggest a genuine trade space rather than a winner: retatrutide currently owns the higher efficacy ceiling, while eloralintide's early signal is about getting meaningful reduction at a lower tolerability cost. Cardiometabolic Endpoints Beyond Body Weight Modern obesity trials are judged on more than the scale. The eloralintide Phase 2 study reported improvements across waist circumference, blood pressure, lipids, glycemic control, and inflammation markers — the standard cardiometabolic risk cluster. This is where the amylin-versus-triple-agonist question gets genuinely open. A triple agonist has mechanistic routes to liver and energy-expenditure effects that a selective amylin agonist does not obviously share. Whether that translates into differentiated outcomes in longer, larger trials is a Phase 3 question, and neither compound has answered it yet. Research-Use Status and Sourcing Neither compound is FDA-approved. Both are investigational, and any vial sold online under either name is a research chemical intended for in-vitro laboratory work — not a medicine, and not something with an approved human dosing schedule. PeptideStack does not publish human protocols for either compound. For laboratory sourcing of eloralintide, Peptide Plugs lists it as "Elora (Eloralintide)" in 5 mg ($70) and 10 mg ($120) vials, with volume discounts scaling to 40% off at 10 or more vials. The listing reports third-party HPLC testing at 99.86% purity with a COA available, and describes the material as a white lyophilized powder with no filler or blend. Code PSTACK is the tracked checkout code on the Peptide Plugs storefront , and our Peptide Plugs promo code page documents where that code goes at checkout. Retatrutide is more widely stocked because it has been in the research-supply market longer. Peptide Partners lists it as "Retatrutide (GLP-3)" , with code KLIKOOGQWG for 10% off; our peptide coupon code directory tracks current vendor offers, and the how to get retatrutide peptide online guide covers what verification documents to demand before buying anything in this category. Which One Matters More Going Forward? Best for raw efficacy ceiling: retatrutide. A 24.2% mean reduction at 48 weeks is the strongest Phase 2 obesity signal in the class, and its Phase 3 program is the one setting expectations for what "next generation" means. Best for the tolerability question: eloralintide. If a selective amylin agonist can hold roughly 20% at the top dose while producing placebo-like adverse-event rates at lower doses, the interesting downstream question becomes combination and sequencing, not replacement. Where the comparison breaks: the moment anyone treats 20.1% and 24.2% as a ranking rather than as two independent observations. Bottom Line Eloralintide vs retatrutide is a mechanism comparison first and a numbers comparison second. Retatrutide asks how much weight reduction is achievable when three metabolic pathways are engaged at once. Eloralintide asks how much is achievable when one pathway is engaged cleanly. Both Phase 2 readouts are legitimate and both compounds remain investigational. The honest position, until a direct comparative trial exists, is that retatrutide has the higher reported ceiling and eloralintide has the more interesting tolerability profile — and no published data ranks one above the other in the same population. Frequently Asked Questions Is eloralintide the same as retatrutide? No. Eloralintide is a selective amylin receptor agonist. Retatrutide is a triple agonist that activates GIP, GLP-1, and glucagon receptors. They are different molecules acting on different biology, both developed by Eli Lilly. Is eloralintide FDA-approved? No. Eloralintide is investigational. Its Phase 2 results were presented at ObesityWeek 2025 and published in The Lancet , and Lilly planned to begin Phase 3 enrollment by the end of 2025. It has no approved indication. Is retatrutide FDA-approved? No. Retatrutide remains investigational, with Phase 2 obesity data published in the New England Journal of Medicine and a Phase 3 program still in progress. Which produced more weight loss in trials, eloralintide or retatrutide? Retatrutide's Phase 2 trial reported up to 24.2% mean weight reduction at 48 weeks. Eloralintide's Phase 2 trial reported 9.5%-20.1% across arms at 48 weeks, about 20.1% at 9 mg, versus 0.4% for placebo. Those figures come from separate trials and are not a ranking. Has there ever been a head-to-head eloralintide vs retatrutide trial? No. No published head-to-head study exists. Any comparison between them is cross-trial and should be read as directional context, not as evidence of superiority. What does "selective amylin receptor agonist" actually mean? It means the molecule is engineered to act at the amylin receptor specifically, rather than engaging incretin receptors such as GLP-1 or GIP. Amylin signaling promotes satiety and slows gastric emptying, which is a different route to reduced food intake than incretin agonism. Why is eloralintide's tolerability profile considered notable? Because gastrointestinal adverse events usually limit dosing across this drug class. In eloralintide's Phase 2 study, GI symptoms were the most common adverse events but were mild to moderate, and incidence was similar to placebo in the lower dose arms. How long were the two Phase 2 trials? Both ran 48 weeks. The eloralintide trial enrolled 263 adults; the retatrutide obesity trial enrolled 338 participants. Both excluded people with type 2 diabetes. Did the eloralintide trial measure anything besides weight? Yes. It reported improvements across cardiometabolic risk factors including waist circumference, blood pressure, lipids, glycemic control, and inflammation markers. Can either compound be used by humans? No. Both are investigational and neither is approved for human use. Vials sold under these names by research suppliers are for laboratory research only and are not medications. PeptideStack does not provide dosing guidance or medical advice. Why do some sources cite 17.5% for retatrutide instead of 24.2%? The 17.5% figure comes from an earlier 24-week readout of the same Phase 2 program. The 24.2% figure is the 48-week result at the highest dose evaluated. Always check the timepoint before comparing percentages. Where does eloralintide fit against CagriSema and cagrilintide? Cagrilintide is an amylin analog paired with semaglutide inside CagriSema, so amylin biology is delivered alongside a GLP-1 agonist. Eloralintide is a standalone selective amylin agonist, which is why its results are read as a test of amylin signaling on its own. The two amylin compounds differ on receptor selectivity rather than mechanism class, which we unpack in our cagrilintide vs eloralintide comparison. References Eli Lilly and Company. Lilly's selective amylin agonist eloralintide demonstrated weight reductions of up to 20.1% in a Phase 2 study. Investor release Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med . 2023;389:514-526. NEJM Disclaimer: This article is for informational and educational purposes only. Eloralintide and retatrutide are investigational compounds and are not FDA-approved for human treatment. Compounds sold under these names are intended for laboratory research use only and are not for human consumption. PeptideStack does not provide medical advice, diagnosis, treatment recommendations, dosing guidance, or instructions for human use. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.